A number of gene mutations have been identified in AML and FLT3 (FMS-like tyrosine kinase 3) ... Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations.
A number of gene mutations have been identified in AML, and FLT3 (FMS-like tyrosine kinase) mutations are the most common.6 Approximately 80% of these FLT3 cases are FLT3-ITD ...